Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
RESEARCH TOOLSreports
Holding SRRK?
Track your performance easily
SRRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.98
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.04M
Market Cap
$4.10B
Enterprise Value$704.92M
Total Cash (Recent Filing)$28.04M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 11, 2025EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding93,614,950
10 Day Avg. Volume1,134,044
30 Day Avg. Volume1,039,598
Standard Deviation0.43
R-Squared0.00424
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3150.50
Price to Cash Flow (P/CF)-19.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue542.24
Enterprise Value/Gross Profit352.46
Enterprise Value/Ebitda-3.18
Forecast
1Y Price Target
$46.33Price Target Upside14.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Scholar Rock Holding News
PremiumCompany Announcements
Scholar Rock Announces Leadership Changes and Strategic Growth
PremiumCompany Announcements
Scholar Rock Highlights Apitegromab Progress at JP Morgan
Bulls Say, Bears Say
Bulls Say
Clinical SuccessPositive topline results were announced from the SAPPHIRE trial, showing consistent and clinically meaningful benefits for apitegromab in non-ambulatory patients with spinal muscular atrophy.
Market OpportunityThe SMA market opportunity could be larger than anticipated given the removal of this competitive overhang.
Strategic PositioningSRRK is now considered an attractive M&A acquisition candidate for global biopharma players in SMA and CNS neuro with upside on the obesity angle.
Bears Say
Clinical TrialsBHVN Phase III study of taldefgrobep alfa did not hit with no statistical separation vs placebo on the primary endpoint of MFM-32.
Competitive PressureCompetitor BHVN Phase III SMA data may be an overhang for Scholar Rock Holding.
Market SentimentInvestors are a bit nervous into BHVN upcoming Phase III SMA taldefgrobep alfa myostatin data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $6.76 and its highest was $46.98 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $4.10B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Mar 11, 2025 which is in 38 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Nov 12, 2024. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.08.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.6.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 93,614,950 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -5.293%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Among the largest hedge funds holding Scholar Rock Holding Corp’s share is Fisher Asset Management LLC. It holds Scholar Rock Holding Corp’s shares valued at 6M.
---
Scholar Rock Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.33 (14.68% Upside)
$46.33 (14.68% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 638.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $82.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.81%
12-Months-Change
Fundamentals
Return on Equity
-285.33%
Trailing 12-Months
Asset Growth
-28.54%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
---
SRRK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and success in clinical trials, financial strength, and strategic planning for regulatory and commercial milestones. While there is competitive pressure in the obesity market, the overall outlook is positive with robust clinical data and strong financial backing.Read More>---
SRRK Stock 12 Month Forecast
Average Price Target
$46.33
▲(14.68% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Best Analysts Covering SRRK
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+189.59%
assigned a buy rating 4 months ago
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +189.59% per trade.
---